LON:COIL Roquefort Therapeutics H1 2024 Earnings Report GBX 10.12 -0.88 (-7.95%) As of 12:12 PM Eastern ProfileEarnings History Roquefort Therapeutics EPS ResultsActual EPS-GBX 4.50Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ARoquefort Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ARoquefort Therapeutics Announcement DetailsQuarterH1 2024Date9/27/2024TimeBefore Market OpensConference Call DateFriday, September 27, 2024Conference Call Time7:00AM ETConference Call ResourcesInterim ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsInterim report Roquefort Therapeutics Earnings HeadlinesCoiled Therapeutics PLCApril 1, 2026 | barrons.comRoquefort springs over to AIM from Main Market as Coiled TherapeuticsMarch 27, 2026 | lse.co.uk$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…May 21 at 1:00 AM | Paradigm Press (Ad)Coiled Therapeutics' Dr Sotirios Stergiopoulos on Roquefort RTO, AO-252 cancer trial updateMarch 9, 2026 | uk.finance.yahoo.comSmall cap idea: Why this £40m bet on an emerging cancer treatment may be perfectly timedMarch 9, 2026 | msn.comWhy this £40m bet on an emerging cancer treatment may be perfectly timedMarch 4, 2026 | uk.finance.yahoo.comSee More Roquefort Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Roquefort Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Roquefort Therapeutics and other key companies, straight to your email. Email Address About Roquefort TherapeuticsCoiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is supported by a leadership team with a proven track record in drug development and strategic backing from A2A Pharmaceuticals. https://coiledplc.com/View Roquefort Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingMeta Platforms 10% Layoff Raises a Bigger Question About AI SpendingTarget Shows Strengths, But Analysts Want to See MoreFreight Boom: The Hormuz Blockade PaydayTJX Companies Fires on All Cylinders With 9% Revenue GrowthAnalog Devices Provides Much-Needed Pullback: How Low Can It Go?USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
